Lead radiopharma Oncoinvent is a clinical stage radiopharmaceutical company focusing on alpha-emitting therapies for metastatic cancers, presenting a ready-to-engage pipeline (Radspherin) for hospitals and cancer centers seeking innovative radionuclide treatments.

Strategic collaboration Recent partnerships and mergers, including ARTBIO collaboration and the BerGenBio merger, indicate a readiness to expand capabilities and distribution channels, suggesting opportunities for joint development, licensing, or co-commercialization discussions.

C-suite evolution New executive leadership, notably the appointment of a CFO and a CEO within the past two years, signals organizational maturation and potential buying cycles lengthening with formal budgeting and procurement processes.

Global outreach Headquartered in Oslo with cGMP-compliant laboratories and focus on clinical trials points to targets in Europe and affiliated research networks; potential to engage multinational hospitals, clinical trial networks, and radiopharmacy suppliers as customers or partners.

Financial momentum Revenue in the mid-range range and the latest funding indicate capacity for scaled manufacturing and phase-appropriate clinical collaborations, presenting opportunities for pilot studies, contract manufacturing, and downstream radiochemistry services.